ReviewClinical proteomics2016
Precision medicine: from pharmacogenomics to pharmacoproteomics.
Review in Clinical proteomics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Pharmacogenomics of antibacterial and antiviral therapies: Clinical actionability, evidence gaps, and future directions.Pharmacological reviews · 2026Review
- Are Hospital Pharmacists Ready for Precision Medicine in Nigerian Healthcare? Insights From a Multi-Center Study.Health care science · 2025Article
- Pharmacogenomics revolutionizing cardiovascular therapeutics: A narrative review.Health science reports · 2024Article
- Sepsis, Management & Advances in Metabolomics.Nanotheranostics · 2024Review
- Performance Comparisons of AlexNet and GoogLeNet in Cell Growth Inhibition IC50 Prediction.International journal of molecular sciences · 2021Article
- Precision Medicine in Kidney Transplantation: Just Hype or a Realistic Hope?Transplantation direct · 2021Article
- Pharmacoproteomics Identifies Kinase Pathways that Drive the Epithelial-Mesenchymal Transition and Drug Resistance in Hepatocellular Carcinoma.Cell systems · 2020Article
- Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)-Based Proteomics of Drug-Metabolizing Enzymes and Transporters.Molecules (Basel, Switzerland) · 2020Review
- High-Resolution Melting Assay for Genotyping Variants of the CYP2C19 Enzyme and Predicting Voriconazole Effectiveness.Antimicrobial agents and chemotherapy · 2019Article
- Biotransformation profiles from a cohort of chronic fatigue women in response to a hepatic detoxification challenge.PloS one · 2019Observational
- Biomarkers: Delivering on the expectation of molecularly driven, quantitative health.Experimental biology and medicine (Maywood, N.J.) · 2018Review
- DrugBank 5.0: a major update to the DrugBank database for 2018.Nucleic acids research · 2018Article
- Discovery of the Consistently Well-Performed Analysis Chain for SWATH-MS Based Pharmacoproteomic Quantification.Frontiers in pharmacology · 2018Article
- Environmental influences in the etiology of colorectal cancer: the premise of metabolomics.Current pharmacology reports · 2017Article
- Historical root of precision medicine: an ancient concept concordant with the modern pharmacotherapy.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2017Article
- Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Disease progression and drug response may vary significantly from patient to patient. Fortunately, the rapid development of high-throughput 'omics' technologies has allowed for the identification of potential biomarkers that may aid in the understanding of the heterogeneities in disease development and treatment outcomes. However, mechanistic gaps remain when the genome or the proteome are investigated independently in response to drug treatment. In this article, we discuss the current status of pharmacogenomics in precision medicine and highlight the needs for concordant analysis at the proteome and metabolome levels via the more recently-evolved fields of pharmacoproteomics, toxicoproteomics, and pharmacometabolomics. Integrated 'omics' investigations will be critical in piecing together targetable mechanisms of action for both drug development and monitoring of therapy in order to fully apply precision medicine to the clinic.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.